Tarsus Pharmaceuticals Inc (NAS:TARS)

Q1 2025 Tarsus Pharmaceuticals Inc Earnings Call Transcript

May 1, 2025 / 08:30 PM GMT

Release Date Price: $50.3 (-3.10%)

Transcript 10-Q8-K

Key Points

Positve

Tarsus Pharmaceuticals Inc (TARS) reported a significant year-over-year increase of 217% in sales for their product Exteny, generating over $78 million in the first quarter of 2025.
The company has achieved broad commercial and Medicare coverage, with more than 90% of lives covered, eliminating a major barrier to physician adoption.
Tarsus Pharmaceuticals Inc (TARS) successfully secured approximately $135 million through an equity financing, strengthening their financial position.
The company's direct-to-consumer (DTC) campaign has significantly increased website traffic by 140% and is driving patient engagement.
Tarsus Pharmaceuticals Inc (TARS) is making progress in expanding globally, with potential European regulatory approval for Exteny expected in 2027 and exploring opportunities in Japan.

Negative

Operating expenses increased to approximately $104.6 million, driven by direct consumer advertising and other commercial marketing costs.
The gross-to-net discount for Exteny was approximately 47%, reflecting adjustments and impacting net revenue.
There is uncertainty regarding the impact of potential tariffs, although the company believes it would be insignificant.
The company anticipates more modest revenue growth in the third quarter due to typical sector summer dynamics.
Despite strong sales, Tarsus Pharmaceuticals Inc (TARS) has not provided long-range guidance on achieving cash flow positivity, as they continue to invest in pipeline development.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TARS.OQ - Tarsus Pharmaceuticals Inc
Q1 2025 Tarsus Pharmaceuticals Inc Earnings Call
May 01, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day ladies and gentlemen, and thank you for standing by. Welcome to the Tarsus first quarter 2025 earnings conference call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question and answer session. If you would like to ask a question at that time, please press 11 on your telephone keypad. As a reminder, this conference call is being recorded. At this time, I would like to turn the conference over to Mr. David Ncasoni. Sir, please begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you. Before

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.